Wilmington, Delaware – AstraZeneca has announced the acquisition of Modella AI (https://www.modella.ai/). According to the company announcement AstraZeneca is a global biopharmaceutical company actively transforming its drug discovery and clinical development through the strategic deployment of innovative and impactful AI solutions. The company has recently acquired Modella AI, a leader in artificial intelligence for life sciences, to expand its existing collaboration and advance AI-driven oncology research and development at a global scale. This acquisition integrates Modella AI’s generative and agentic AI platform into AstraZeneca’s oncology R&D organization, aiming to accelerate clinical development, enhance biomarker discovery, and enable data-driven decision-making across its pipeline. AstraZeneca’s focus on oncology drug development is becoming increasingly complex, data-rich, and time-sensitive, necessitating powerful and deployable AI solutions in global trials and clinical settings. The integration of Modella AI’s state-of-the-art pathology foundation models and AI agents will further enable the development of targeted therapeutics and diagnostics within AstraZeneca’s oncology portfolio.

To learn more about AstraZeneca, visit https://www.astrazeneca.com/
Company LinkedIn Page: https://www.linkedin.com/company/astrazeneca/

Company Contact:

AstraZeneca
1800 Concord Pike
Wilmington, DE 19850
800-456-3669

SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved.